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ABSTRACT 
Background: Acute graft-versus-host disease (aGVHD), following allogeneic 
hematopoietic stem cell transplantation (HSCT), is a potentially life-threating condition. 
Gastrointestinal involvement of aGVHD (GI-aGVHD) affects approximately every fourth 
transplanted child. The diagnosis of GI-aGVHD is primarily symptom-based. However, symptoms 
associated with GI-aGVHD are nonspecific; thus, histopathological confirmation of the diagnosis, 
is recommended. The overall objectives of this thesis were: i) to evaluate the influence of two 
different conditioning regimens on the incidence of GI-aGVHD, and ii) to evaluate clinical aspects 
of the currently recommended diagnostic approach to GI-aGVHD, i.e., endoscopy-guided 
histopathological assessment, applied to pediatric HSCT patients.   
Patients and methods: Four retrospective cohort studies were included in this 
thesis. Paper I enrolled all children with HSCT performed during 2000–2010 at Karolinska 
University Hospital Huddinge who also had underlying diagnoses of juvenile myelomonocytic 
leukemia (JMML) or myelodysplastic syndrome (MDS). The children were conditioned with 
busulfan (Bu) and cyclophosphamide (Cy), with or without addition of melphalan (Mel). Paper II-
IV included all children who underwent HSCT at any of the four HSCT centers in Sweden between 
2000 and 2012 and with endoscopy-guided histopathological assessment performed to confirm 
symptom-based GI-aGVHD within one-year post-HSCT. In paper III-IV a retrospective, blinded, 
histopathological assessment (RIHA) was carried out based on the National Institutes of Health 
(NIH) 2014 criteria for histopathology-based GI-GVHD. Paper IV only included those with at least 
a biopsy sampling from the rectosigmoid area and the area proximal to the left colonic flexure.
 Results: Paper 1: Twenty-five children were enrolled. Forty-seven percent (8/17) of 
the children that received addition of Mel to the BuCy conditioning, versus none (0/8) in the BuCy 
group, developed GI-aGVHD (stages 2-4) (p<0.05). Paper II: Based on 68 children with 91 
endoscopic occasions, treatment changes in response to histopathology reports occurred in 48% 
(44/91). Paper III: Seventy children with 92 endoscopic occasions were assessed. Histopathology-
based GI-GVHD diagnosis was established in 67 of 92 (73%) endoscopic occasions in the RIHA 
and in 50 of 92 (54%) in the clinical standard histopathological assessment (p=0.014). The risk of 
a subsequent re-endoscopy within one-year post-HSCT was higher in endoscopic occasions with 
GI-GVHD solely detected in RIHA versus non-GI-GVHD in both assessments (p=0.005). Paper 
IV: Forty-four children with 51 endoscopic occasions were analyzed. Biopsies from the 
rectosigmoid area had 85% sensitivity for RIHA-based GI-GVHD diagnosis. The corresponding 
figure for combined biopsy sampling from both rectosigmoid area and upper gastrointestinal tract 
was 97% and was similarly high compared with biopsies collected from complete lower endoscopy. 
 Conclusions: I) Addition of Mel to the BuCy conditioning increased the incidence 
of symptom-based GI-aGVHD in children with JMML and MDS. II) Endoscopy-guided 
histopathological assessment was found to influence the treatment decisions and should therefore 
be considered in children with GI-aGVHD. III) In children with symptom-based GI-aGVHD, 
without confirmation of the diagnosis by clinical standard histopathological assessment, a second 
histopathological assessment based on the NIH 2014 criteria should be considered before 
performing a re-endoscopy. IV) Sigmoidoscopy combined with upper endoscopy, 
colonoscopy/ileocolonoscopy, or full upper and lower endoscopy should be considered as preferred 
choices for the endoscopic procedure in children with clinically suspected GI-aGVHD.  
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1 GENERAL BACKGROUND 
 
1.1 HISTORICAL OVERVIEW  
1.1.1 Allogeneic hematopoietic stem cell transplantation  
The era of allogeneic hematopoietic stem cell transplantation (HSCT) began in the 1950s when 
Vos et al. (1) and Barnes et al. (2) exposed mice to supra-lethal doses of irradiation, followed 
by intravenous infusion of bone marrow cells from mice of a different strain. Barnes et al. used 
mice with leukemia and showed that the malignancy was most often eradicated by this 
procedure. However, in both studies, the majority of the animals experienced a “delayed” death 
that was preceded by profuse diarrhea and reduced body weight (1, 2). The observed syndrome 
was called the secondary disease, later renamed graft-versus-host disease (GVHD). 
GVHD was studied in depth by van Bekkum et al., who described GVHD as a multiorgan 
failure, affecting the skin, gastrointestinal tract and liver (3). A breakthrough in creating the 
prerequisites for introduction of HSCT in clinical practice came in the mid–late 1960s with the 
discovery of Human Leukocyte Antigens (HLA), the major trigger of alloreactivity, and the 
development of drug regimens to protect against and treat GVHD. 
In 1968, reports in The Lancet described the first two children treated with HSCT (4, 5). Seven 
years later, Huddinge Hospital/Karolinska University Hospital Huddinge performed the first 
HSCT in a Swedish child. Within a few years, HSCT became an established treatment 
procedure for children in Sweden. 
1.1.2 Pediatric gastrointestinal endoscopy  
The first endoscopy-like instrument, the lichtleiter, was introduced by the German physician 
Philip Bozzini in 1805 (6). The instrument was rigid and used candlelight for illumination. Its 
rigidity and poor illumination constrained the use of the lichtleiter in clinical practice. Modern, 
fully flexible endoscopes were introduced in 1957 and flexible GI endoscopes for children 
appeared in clinical practice in the 1970s (6).  
The first pediatric endoscopy for diagnostic of GVHD in the gastrointestinal tract was 
performed in 1968 (5). A five-month-old boy with sex-linked lymphopenic immunological 
deficiency underwent HSCT, with his eight-year-old sister as the stem cell donor. At 
approximately two weeks post-HSCT, the boy developed bloody diarrhea. During proctoscopy 
with biopsy sampling, small mucosal ulcers were observed. The subsequent histopathological 
assessment of collected biopsies revealed crypt lesions, moderate mononuclear cell infiltration, 
and increased numbers of mast cells and eosinophils. The histopathological pattern was 
interpreted as gastrointestinal GVHD. Fortunately, the boy recovered and was discharged from 
the hospital at two months post-HSCT. 
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Today, endoscopy with biopsy sampling, followed by histopathological assessment, is the 
overall recommended diagnostic procedure to attribute GI symptoms that develop post-HSCT 
to gastrointestinal GVHD (7-9). 
 
1.2 INDICATION OF PEDIATRIC ALLOGENEIC HEMATOPOIETIC STEM CELL 
TRANSPLANTATION 
Approximately 40–50 children under 18 years of age undergo HSCT annually in Sweden. 
Roughly 50 % of the HSCTs are performed due to malignant blood diseases, with the most 
common being acute lymphoblastic leukemia, followed by acute myeloid leukemia (10, 11). 
The remaining 50 % represents a spectrum of non-malignant diseases, such as 
hemoglobinopathies, bone marrow failure, severe immune deficiencies, and metabolic diseases 
(10, 12).  
 
1.3 TRANSPLANTATION PROCEDURE  
1.3.1 Considerations during the pre-HSCT process 
1.3.1.1 Donor 
A HLA mismatch between stem cell donor and the recipient is the most substantial risk factor 
for the development of GVHD (13-15). Siblings, followed by parents, are first investigated as 
potential donors. As the second source, a potential donor is searched through international live 
donor registries, such as the National Marrow Donor Program and the Tobias Registry or 
through accredited public umbilical cord blood banks. The selection of a donor is primarily 
based on the best possible HLA matching between recipient and donor, with preference for a 
matched sibling donor (16). Beyond HLA compatibility, serological-based matching of 
cytomegalovirus (CMV), Epstein-Barr virus (EBV) is preferred, and furthermore, a younger 
donor is preferred compared with an older one, as well as avoidance of female-donor-to-male-
recipient transplantation (16). 
1.3.1.2 Stem cell source  
Potential stem cell sources are bone marrow, peripheral blood stem cells, and umbilical cord 
blood. The choice of stem cell source, if several are available, is based on the probability that 
each might increase the risk of GVHD, relapse (i.e., recurrence of the underlying disease that 
was the indication for the transplantation), and graft failure (16, 17). The choice of stem cell 
source also depends on the underlying diagnosis of HSCT and the donor preference of donation 
method (16). In children, bone marrow is the most frequently used stem cell source, whereas it 
is peripheral blood stem cells in adults (18). 
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1.3.1.3 Conditioning regimen  
The conditioning or preparative regimen refers to chemotherapy with or without simultaneous 
irradiation administered before the infusion of the graft. The conditioning regimen induces 
immunosuppression in the recipient, thereby enabling engraftment, thus avoiding rejection of 
the graft (19). The conditioning regimen also provides an antitumor effect (19).  
The two main categories of conditioning regimen are myeloablative conditioning (MAC) and 
reduced intensity conditioning (RIC). MAC is an extensive conditioning regimen and was 
previously regarded as the gold standard if the indication for HSCT was malignant blood 
disease. However, growing evidence now indicates that RIC can be used instead of MAC, since 
eradication of malignant cells is more related to the so-called graft-versus-tumor (GVT) effect 
than to the intensity of the conditioning regimen (20). 
1.3.1.4 GVHD prophylaxis 
GVHD prophylaxis consists of immunosuppressive drugs to reduce the risk of development of 
GVHD. The thymus-derived lymphocytes (T-cells) of the graft are the target cells of this 
prophylaxis. The choice of prophylaxis is based on an integrated analysis of each patient 
regarding the occurrence of factors that may increase the risk of GVHD. The dosage and 
duration of the prophylaxis depends on whether a malignant or a non-malignant disease is the 
underlying diagnosis for the HSCT. If the underlying diagnosis is a non-malignant disease, no 
GVT effect is needed; therefore, higher doses and a longer duration of the prophylaxis are 
preferred.  
In children, the standard GVHD prophylaxis is cyclosporine A, combined with a short course 
of methotrexate (21). Polyclonal anti-thymocyte globulin (ATG) is most often added if the risk 
of GVHD is elevated, such as in cases with a HLA-matched unrelated donor or a HLA 
mismatched donor (19, 21). In a high-risk situation for GVHD, such as in haploidentical stem 
cell transplantation (stem cells from one of the parents), the addition of two doses of 
cyclophosphamide post-HSCT (PT-Cy) might be an option (22).    
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 Figure 1. Schematic overview of the HSCT process (21, 23-25)  
 
1.3.2 The HSCT process 
A schematic overview of the HSCT process is presented in figure 1.  
1.3.2.1 Engraftment 
Engraftment indicates that the graft has survived and has started to produce new hematological 
cells. Neutrophil engraftment is defined as absolute neutrophil count of > 0.5 × 109 cells/L over 
three consecutive days, whereas platelet engraftment is defined as levels of platelets of >20 × 
109 cells/L over seven consecutive days (26).  
Engraftment occurs most frequently at two weeks after the transplantation if peripheral blood 
stem cells are used and approximately three weeks post-HSCT in bone marrow transplantation 
(27). Engraftment indicates the time point at which the clinical onset of GVHD may occur (23).  
Conditioning  
• 7-14 days before HSCT
• The conditioning regimen is administered
• Liver damage propholylaxis with ursodeoxycholic acid
HSCT
• Designated as day 0
• Transfusion of stem cells 
• Start of GVHD prophylaxis, most commonly cyclosporine A with a short course of methotrexate
Aplastic phase 
• Very low to non-measurable levels of immune cells
• Patient isolated due to high risk for severe bacterial and fungal infections
• Antibacterial prophylaxis during neutropenia
• Invasive fungal infection prophylaxis considered  
Neutrophil 
engraftment
• Approximately day +14 to day +21 (depends on stem cell source)
• Neutrophil granulocytes > 0,5 × 109/L during three consecutive days
• aGVHD or cGVHD may develops   
Early 
engraftment  
phase
• From engraftment and approximately up to 100 days post-HSCT
• Reconstitution of innate immune cells 
• Increase risk of P. jirovecii (prophylaxis highly recommended) and viral infection (de novo or 
re-activation)
Mid to late 
engrament phase
• From approximately day 100 and up to years post-HSCT 
• Stepwise reconstitution of B- and T-cells 
• Tapering of GVHD prophylaxis considered, three months post-HSCT if underlying malignant 
disease and six months post-HSCT in non-malignant disease as indication of HSCT  
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1.4 ACUTE AND CHRONIC GRAFT-VERSUS-HOST DISEASE  
The National Institutes of Health (NIH) classifies GVHD into two entities: acute GVHD 
(aGVHD) and chronic GVHD (cGVHD) (28). However, in daily clinical practice, the 
distinction between these two is sometimes problematic. Furthermore, overlap GVHD, a 
subgroup of cGVHD with features of both acute and chronic GVHD occurring simultaneously, 
is a defined subgroup (28). 
1.4.1 Acute GVHD   
Acute GVHD is primarily a symptom-based diagnosis when it affects the skin or the GI tract. 
In acute liver–GVHD, the diagnosis is based on elevated serum bilirubin (Table 1). In classical 
aGVHD, the onset of symptoms occurs within 100 days post HSCT (29). In late onset and 
persistent aGVHD, the onset of symptoms is observed after, or persists beyond, 100 days post 
HSCT (29).  
 
 
 
Table 1. Staging of acute GVHD in children (bodyweight < 50 kg) and in adolescents or 
adults (bodyweight >50 kg), in accordance with The Mount Sinai Acute GVHD 
International Consortium# 
Stage Skin LiverA Upper GI tract Lower GI tract  
0 No active GVHD 
rash 
< 34 μmol/L    
1 Maculopapular rashB 
<25% BSA 
34-50 μmol/L Persistent nauseaC, 
vomitingD or 
anorexia with 
weight loss 
<50 kg, diarrheaE10-19.9 
mL/kg/day or 4-6 episodes/day 
>50 kg, diarrheaE 500-999 
mL/day or 3-4 episodes/day 
2 Maculopapular rash B 
25-50% BSA  
 51-102 
μmol/L 
 <50 kg, diarrheaE 20-30 
mL/kg/day or 7-10 episodes/day 
>50 kg, diarrheaE 1000-1500 
mL/day or 5-7 episodes/day 
3 Maculopapular rashB 
>50% BSA 
103-255 
μmol/L 
 < 50 kg, diarrheaE >30 
mL/kg/day or >10 episodes/day 
>50 kg, diarrheaE >1500 
mL/day or >7 episodes/day 
4 ErythrodermaB 
>50% BSA and 
bullous formation 
and desquamation 
>5% BSA 
> 255 μmol/L  Severe abdominal painF with or 
without ileus or 
grossly bloody stool (regardless 
of stool volume) 
AHyperbilirubinemia developed simultaneously or after onset of acute GVHD in the skin or in the GI tract, and non-
GVHD causes of hyperbilirubinemia ruled out with reasonable certainty. BHyperpigmentation excluded.  
CAt least during three consecutive days. DAt least two vomiting episodes during two consecutive days.  
EFrequencies of defecations or volumes of diarrheas (preferably) calculated as an average during three consecutive 
days. FSubstantial impact of the performance status and requiring initiating of high doses of narcotic pain relief 
medication or substantial dose escalating, if ongoing medication at onset of stage IV acute GVHD in lower GI tract. 
#Published with kindly permission of The Mount Sinai Acute GVHD International Consortium (Harris et al, Biol 
Blood Marrow Transplant 2016) 
(GVHD: Graft-versus-host disease, BSA: Body skin area, GI: Gastrointestinal tract)  
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1.4.1.1 Severity staging and grading 
A disease severity scoring system for aGVHD was developed in the 1970s (30). It was modified 
in 1994 to the so-called modified Glucksberg or Keystone criteria (31), followed by further 
minor revisions. Today, several different scoring systems exist. However, in the context of 
clinical aGVHD research, The European Society for Blood and Marrow Transplantation 
(EBMT), The NIH and The Center for International Blood and Marrow Transplant Research 
(CIBMTR), recommend the aGVHD staging/grading system of The Mount Sinai Acute GVHD 
International Consortium (MAGIC) (32).  
The scoring of aGVHD is based on the disease severity in the skin, liver, and GI tract (Table 
1). The disease stage (0–4) in each affected organ is used to provide an overall disease severity 
grade (1–4) (Table 2). The overall disease severity grade corresponds inversely to the 
probability of survival. Roughly, the higher overall disease severity grade, the lower probability 
of survival (33).  
 
 
1.4.1.2 Frequency of aGVHD 
Overall, aGVHD affects approximately 55–75 % of children treated with HSCT (34, 35) and 
grade 2–4 aGVHD approximately 40 % (11, 36). If severity grades 2-4 of aGVHD are 
considered, the skin is the most frequently affected, followed by the GI tract and the liver (36), 
with an estimated incidence of aGVHD with involvement of the gastrointestinal tract (GI-
aGVHD) in children of approximately 15–25 % (36, 37).  
However, in severe aGVHD, the proportion of affected organs might be different (15, 38). In 
a retrospective study including 50 children with aGVHD grade 3-4, 94 % (47/50) had 
involvement of the gastrointestinal (GI) tract, either as a solitary manifestation of aGVHD or 
together with simultaneous aGVHD in the liver or the skin (15).    
 
Table 2. Overall grading of acute graft-versus-host disease in accordance with The 
Mount Sinai Acute GVHD International Consortium# 
Grade Skin  Liver  Upper GI 
tract 
 Lower GI tract 
0 -  -  -  - 
1 Stage 1-2  -  -  - 
2 Stage 3 and/or    Stage 1 and/or Stage 1 and/or           Stage 1 
3   Stage 2-3   and/or    Stage 2-3 
4 Stage 4 and/or    Stage 4   and/or           Stage 4 
 #Published with kindly permission of The Mount Sinai Acute GVHD International Consortium (Harris et al, Biol 
Blood Marrow Transplant 2016) 
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1.4.1.3 Risk factors for development of aGVHD 
The most important risk factor for development aGVHD is a HLA mismatch between the donor 
and recipient (13-15). However, several other risk factors have been identified, such as 
recipient age >12 years at the time of HSCT (39), malignant disease as indication for the 
transplantation (11), use of an unrelated donor or a female donor to a male recipient (14), use 
of peripheral blood stem cells as the stem cell source (40), poor oral nutrition (41, 42), previous 
damage to the GI tract (43-45), and conditioning with total body irradiation (TBI) (46). 
1.4.2 Chronic GVHD 
Symptoms of cGVHD may develop at any time after engraftment. The clinical phenotype of 
cGVHD mimics autoimmune disease and may affect almost every organ system in the body 
(47). Presentation of cGVHD may include dry eyes, lichenoid lesions of the oral cavity, 
scleroderma, alopecia, joint stiffness, hepatitis, exocrine pancreatic insufficiency, wasting 
syndrome, obstructive lung problems, thrombocytopenia, and lymphocytopenia (28).  
The NIH has developed diagnostic criteria for cGVHD to improve the diagnostic accuracy and 
reproducibility of cGVHD in clinical research (28). In clinical practice, however, many patients 
will not meet the NIH criteria but may still be helped by cGVHD treatment (47).  
Based on the NIH criteria, findings solely of esophagus strictures or webs are accepted 
diagnostic manifestations of gastrointestinal c-GVHD (GI-cGVHD) (28). Thus, common GI 
symptoms of GI-aGVHD and GI-cGVHD, such as diarrhea, nausea or vomiting, and anorexia, 
are, in accordance with the NIH criteria, classified as GI-aGVHD (28). 
1.4.2.1 Frequency of cGVHD 
Based on the NIH cGVHD consensus criteria, approximately 20–40 % of children undergoing 
HSCT develop cGVHD (48, 49), with the mouth, skin, eyes, and lungs as the most commonly 
affected organs (48, 49). By contrast, esophageal strictures or webs are rare (48).  
1.4.2.2 Risk factors for development of cGVHD 
A previous history of aGVHD is the strongest risk factor for the development of cGVHD (14, 
48, 49). Thus, the risk factors associated with the development of aGVHD are also valid risk 
factors for the development of cGVHD (14).  
 
1.5 HUMAN LEUKOCYTE ANTIGENS 
HLA are highly polymorphic cell surface immunoglobulins that are encoded on the short arm 
of chromosome 6. HLA have both antigenic and antigen presenting properties.  
Two classical classes of HLA have been defined: HLA 1 and 2. HLA class 1 are expressed on 
all nucleated cells, whereas HLA class 2 are predominantly expressed on antigen-presenting 
cells (APCs), such as dendritic cells, macrophages, and bone marrow derived B-lymphocytes 
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(B-cells). HLA class 1 presents peptides from intracellular pathogens or peptides of 
intracellular components on the cell surface. The HLA class 1 + ligand complex is recognized 
by CD8+ T-cells. HLA class 2 presents extracellular components, such as fragments from 
extracellular bacteria, for the immune system. The activation of CD4+ T-cells depends on 
recognition of the HLA class 2 + ligand complex.  
1.5.1 T-cell alloreactivity 
T-cell alloreactivity is triggered by genetic differences between two different individuals and 
is fundamental in the pathophysiology of aGVHD (50). However, alloreactive T-cells are also 
essential in the desirable GVT reaction (51).     
1.5.1.1 HLA-based alloreactivity 
The alloreaction in aGVHD is primarily based on differences in HLA between the donor and 
recipient. The reaction is induced when donor T-cells recognize the non-self HLA+ligand 
complex in the recipient. That identification triggers an immune response that causes tissue 
damage (52). 
1.5.1.2 Non-HLA-based alloreactivity  
Non-HLA-based alloreactivity refers to T-cells of donor origin recognizing peptides encoded 
by polymorphic genes outside the HLA locus as foreign. These immunogenic peptides are 
called minor histocompatibility antigens (mHA). 
Development of aGVHD in an HLA identical HSCT setting has been associated with 
differences in mHA between the donor and recipient (53). Furthermore, the increased risk of 
aGVHD associated with female (X X) to male (X Y) transplantation has been associated with 
mHA encoded on the recipient Y chromosome (54, 55). 
1.5.1.3 Alloreactivity in GVT 
GVT alloreaction refers to properties of the graft that eradicate tumor cells in the recipient. 
Subsets of the graft T-cells, such as natural killer (NK) cells and γδ-T-cells, have been identified 
as important for this reaction (20). 
1.5.1.4 The dual effect of mHA alloreactivity 
The GVT reaction is closely tied to the risk of aGVHD (53). Which immunological phenotype 
that will predominate have been proposed to depend on whether the mHA that triggers the 
alloreaction is broadly expressed on many different cell types or whether it is restricted to cells 
of the hematopoietic system (53). If mHA is restricted to cells of the hematopoietic system, 
then a GVT reaction will predominate (53). However, if the mHA is broadly expressed on 
many cell types and tissues, then the probability of occurrence of both GVHD and GVT 
increases. Broadly expressed mHA has also been proposed to explain the inverse association 
between the disease severity grade of aGVHD and the risk of relapse (33). 
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Taken together, the current data indicate that low-grade aGVHD might be a beneficial sign in 
individuals undergoing HSCT due to malignant blood disease. This is because low-grade 
aGVHD might indicate an alloreaction, based on mHA, that is predominantly expressed on 
hematological cells and thus on the malignant cells as well.  
 
1.6 PATHOPHYSIOLOGY OF ACUTE GRAFT-VERSUS-HOST DISEASE 
In 1966, Rupert E Billingham formulated the following three prerequisites for development of 
GVHD: the graft must consist of immune cells (T cells), the recipient should not be able to 
eliminate the transplanted cells, and the graft and the recipient must express different tissue 
antigens (56). The prerequisites formulated by Billingham have been confirmed in all essential 
aspects, even though data concerning the pathophysiology of GVHD is primarily based on 
knowledge derived from animal studies (57).   
1.6.1 Development of acute GVHD 
Development of aGVHD is a multistep process. The basis of the process is a HLA or mHA 
mismatch between the donor and recipient (Figure 2). 
 
 
Figure 2. The pathophysiology of acute graft-versus-host disease 
 
1.6.1.1 Tissue damage and activation of innate immunity 
The aGVHD process is initiated by tissue damage generated by the conditioning regimen or 
other tissue-damaging processes (43-45, 58). The tissue damage will cause a release of 
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intracellular molecules and may also make possible a translocation of extracellular/exogenous 
molecules.  
Tissue damage of the GI tract will enable translocation of luminal exogenous molecules, such 
as bacteria or bacterial fragments, into the bowel wall. If bacteria are translocated, then blood 
stream infections may occur prior to clinically apparent aGVHD (59). Furthermore, fragments 
of bacteria, such as endotoxin/lipopolysaccharides (LPS), may also adhere to toll-like receptors 
(TLRs) on various cell types in the bowel wall, including epithelial cells, fibroblasts, dendritic 
cells and macrophages (60). In these cell types, the TLR-LPS complex activates the production 
of pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α), interleukin (IL)-
1, IL-6, and IL-12 (60). These cytokines will, among other things, act as chemo-attractants, as 
well as inducing increased expression of adhesion molecules on endothelial cells. These 
responses, all together, lead to the migration of neutrophils, eosinophils, and macrophages into 
the damaged tissue (52, 61). However, some cytokines, such as TNF-α, may cause further 
tissue damage by induction of programmed cell death, i.e., apoptosis (62).  
Injured or necrotic cells release several different molecules, such as uric acid, adenosine 
triphosphate (ATP), and IL-33. These molecules, together with LPS, IL-12, and TNF-α, have 
properties that activate APCs (63). Activated APCs may in the following step activate T-cells 
of donor origin (63), thereby bridging tissue damage and innate immune activation with an 
adaptive immune response during the development of aGVHD. 
1.6.1.2 Activation of T-cells of donor origin 
Activated CD8+ cytotoxic effector T lymphocytes (CTLs) are the major effector cells in the 
pathophysiology of aGVHD. Induction of lysis, due to perforation of the target cell membrane 
or induction of apoptosis, are the mechanisms by which CTLs induce tissue damage in aGVHD 
(64).  
The activation of CTLs may be triggered: i) by HLA class 2 on APCs, presenting degraded, 
disparate HLA or mHA proteins to Helper CD4+ T-cells (Th cells) of donor origin, or ii) 
directly by HLA class 1 molecules (52). The HLA class 2 pathway induces proliferation and 
differentiation of the Th-cells, which will be followed by production of certain cytokines, such 
as IL-2 and interferon-gamma (IFN-γ) (52, 65). These cytokines are, among other things, 
responsible for the activation of CTLs as well as macrophages (52).   
Taken together, results from previous studies show that activated CTLs are the major effector 
cells in the pathophysiology aGVHD. However, other cell types, such as 
monocytes/macrophages, in concert with the toxic effect exerted by different cytokines, also 
contribute to the aGVHD-related tissue destruction (52, 66).   
1.6.1.3 Commensal microbiota   
The impact of the GI microbiota on the pathophysiology of aGVHD was discovered by Van 
Bekkum et al. in 1974 (67). These researchers observed that the incidence of and the mortality 
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due to aGVHD were significantly higher in conventional mice than in mice kept in germ-free 
state after lethal irradiation followed by allogeneic bone marrow transplantation (67). 
The concept discovered by Van Bekuum et al has been difficult to apply to human HSCT 
recipients. Only approximately 50 % of children treated from day -10 until day +30 with high 
doses of non-absorbable antimicrobial drugs and nursed in strict isolation were able to achieve 
“germ-free” GI tracts (68). Instead, treatment with a broad-spectrum antibiotic at the time point 
of the HSCT has in human HSCT recipients been associated with a reduced diversity of the gut 
commensal microbiota (dysbiosis) (69), increased risk of GI-GVHD (69), and an increased 
probability of mortality within 3 years post HSCT (70, 71).  
Changes in the composition of the microbiota in HSCT patients include increased proportions 
of Enterococcus spp. (69, 72) and Escherichia coli (E. coli) (71, 72), as well as reduced 
proportions of the Clostridium cluster (69, 73). These changes in the microbiota may, however, 
not be fully explained by antibiotic treatment (70). Another contributing factors may be a 
decreased number of Paneth cells in the GI tract epithelium of the small intestine, a finding that 
has been correlated with GI-GVHD (74). Paneth cells secrete anti-bacterial peptides, such as 
regenerating islet-derived 3 alpha (Reg-3-α), that affect E. coli without affecting the 
Clostridium cluster or other commensal bacteria (75). Thus, loss of Paneth cells increases the 
survival possibilities for E. coli, while decreasing the survival properties for the Clostridium 
cluster.  
The Clostridium cluster produces short fatty acid chains, such as butyrate, an important nutrient 
for the intestinal epithelial cells (76). Therefore, a reduction in the number of clostridia may 
induce a nutritional deficiency in the GI tract mucosa. This deficiency may cause GI tract 
damage, thereby increasing the risk for development of aGVHD (73, 76).   
1.6.1.4 Suppression of the immune response  
A non-regulated immune response may cause a vicious cycle, resulting in deleterious tissue 
damage to the host (Figure 2). Avoidance of this cycle requires suppression of the immune 
response. However, in the context of HSCT, this suppression should preferably not encroach 
on the GVT reaction.  
Infusion of regulatory T-cells (T-reg, expressing CD4+, CD25+, and Forkhead Box Protein 3 
[FoxP3]) at day -4 has been associated with a reduced risk for the development of aGVHD 
without impacting the GVT reaction (77).  
However, in a clinical situation with ongoing aGVHD, expression of mRNA for transcription 
factor Foxp3 in peripheral blood mononuclear cells was inversely related to the clinical severity 
grade of aGVHD (78). The highest levels of Foxp3-mRNA expression were observed in 
patients without aGVHD (78). Furthermore, a biopsy-based study that included patients with 
histopathology-based GI-GVHD diagnosis and healthy controls revealed similar T-reg/CD8+ 
T-cell ratios in the healthy controls and in those with GI-GVHD (79). That finding was 
interpreted as an insufficient upregulation of T-regs to counteract aGVHD (79).   
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Taken together, the data indicate that a numerical and/or functional reduction of T-regs may 
cause insufficient suppression of the immune response in aGVHD.  
 
1.7 TREATMENT OF ACUTE GRAFT-VERSUS-HOST DISEASE 
1.7.1 First-line treatment   
The first-line treatment of grade 2–4 aGVHD is 2 mg/kg bodyweight/day of 
methylprednisolone or an equivalent glucocorticoid for seven days, followed by slow tapering 
according to the response (9, 80). Despite a sparse body of evidence (81), mainly non-
absorbable corticosteroids, like beclomethasone or budesonide, are often added to 
methylprednisolone in patients with GI-GVHD (9).  
Upper GI tract manifestations of aGVHD have been shown to be more responsive to treatment 
with steroids (82, 83). Therefore, in individuals solely affected by upper GI tract aGVHD, a 
proposed treatment regimen is an initial ten-day course with methylprednisolone at 1 mg/kg 
bodyweight /day, followed by a fifty-day course of beclomethasone or budesonide (9).   
Overall, the probability of a treatment response to glucocorticoids is lower with a higher disease 
severity grade of aGVHD (80). Non-methylprednisolone-responsive aGVHD i.e., steroid 
refractory aGVHD (SR-aGVHD), has been defined as one of the following: i) progression of 
aGVHD manifestations despite treatment with ≥2 mg/kg bodyweight/day of 
methylprednisolone for 3–5 consecutive days; ii) failure to improve within 5–7 days of 
treatment initiation, or; iii) incomplete response after more than 28 days of steroid treatment 
(32).  
The incidence of overall SR-aGVHD in children has been estimated to be 35 % (84). The 
corresponding incidence in lower GI tract SR-aGVHD has been reported as 30–52 % (36, 84).  
1.7.2 Second-line treatments 
Several agents, such as mycophenolate mofetil or mesenchymal stromal cells, as well as 
monoclonal antibodies directed against the IL-2 receptor on T-cells, against TNF-α, or against 
endothelial cell adhesion molecules, have been evaluated or are currently under evaluation, as 
second-line treatments, either alone or in combination with methylprednisolone. However, 
none of them have yet shown convincing long-term efficacy (80).  
A novel second line aGVHD treatment strategy is inhibitors of Janus-activated kinase 1 and 2 
(JAK 1/2). The JAK 1/2 inhibitors target signaling events downstream of cytokine receptors 
(80). One JAK 1/2 inhibitor, ruxolitinib, has shown promising preliminary results in SR-
aGVHD but has also been associated with serious side effects, such as neutropenia and 
infections (85). Thus, further studies are needed to evaluate the clinical usefulness of 
ruxolitinib.   
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1.8 SURVIVAL   
Currently, approximately three out of four children survive three years post-HSCT, when all 
underlying diagnoses of HSCT are considered  (11, 34).  
Several factors that pre-exist before HSCT have been associated with a less favorable 
probability of survival. These factors include; malignant blood disease as indication for the 
transplantation; HSCT performed in children below one year of age; HLA mismatch between 
donor and recipient; use of an unrelated donor; a serological-based CMV mismatch between 
the donor and recipient; female-to-male transplantation; and donor age > 33 years (11, 13, 18, 
86, 87). Factors added after the transplantation that have a substantial negative impact on 
survival are relapse of the underlying diagnosis, infections, and aGVHD grade 3–4 (18, 33, 
34).  
The probability of three-year survival in a cohort of children with aGVHD following HSCT 
due to leukemia were 79–76 % for grade 0–2, 67 % for grade 3, and 42.5 % for grade 4 aGVHD 
(33). The corresponding figure for two-year overall survival in SR-aGVHD has been estimated 
to be 35 % (84).   
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2 THESIS SPECIFIC BACKGROUND 
 
2.1 RATIONALE FOR THE THESIS 
Gastrointestinal aGVHD is associated with bothersome symptoms and poor outcome. The 
treatment of choice, glucocorticoids, is accompanied with risks, such as viral infections. In the 
absence of a response to glucocorticoid treatment, the overall expected two-year survival is 
reduced by approximately 50 %. Thus, a reduction in the risk of development of GI-aGVHD 
is important.   
Histopathological confirmation of symptom-based GI-aGVHD is recommended (7-9). 
However, the clinical importance of this recommendation applied to children is hampered by 
i) the lack of robust data supporting an influence of endoscopy-guided histopathological 
assessment on treatment decisions, ii) the lack of consensus regarding the minimal histological 
criteria for the GI-GVHD diagnosis and, iii) the absence of clarity regarding the optimal extent 
of the endoscopic procedure when the indication of the procedure is to confirm symptom-based 
GI-aGVHD. Thus, several clinical aspects of diagnostic of pediatric GI-GVHD, based on 
endoscopy-guided histopathological assessment, require deeper knowledge.  
 
2.2 DEFINITIONS 
In accordance to the NIH, the minimal histopathological criterion necessary to diagnose 
gastrointestinal GVHD, is finding of crypt apoptosis (8). Apoptosis is, furthermore, a sign of 
ongoing tissue damage and has therefore been proposed to be termed “active” GVHD, 
regardless of the traditional distinction between acute, chronic, and overlap GVHD (88). 
Henceforth in this thesis, the symptom-based diagnosis of gastrointestinal GVHD has been 
termed GI-aGVHD. Furthermore, GI-GVHD has been used for histopathology-based “active” 
gastrointestinal GVHD.    
 
2.3 DIFFERENTIAL DIAGNOSIS 
Infections in the GI tract or side effects of drugs, including the conditioning regimen, may cause 
symptoms indistinguishable from those of GI-aGVHD. In children with diarrhea post-HSCT, 
an infectious cause has been found in 10–20 %, with Clostridium difficile (C. difficile) (89), 
rota-, noro-, adenovirus, and CMV as the most common agents (90-93). However, diarrhea 
caused by infectious parasites or bacterial agents other than C. difficile, has been reported to be 
rare (94).   
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2.3.1 Clostridium difficile  
C. difficile infections (CDIs) have been observed in approximately 8–9 % of children 
undergoing HSCT (37, 89). CDI has a recurrence rate of approximately 20 % (89). The 
diagnosis of CDI rests on a positive fecal toxin assay, together with typical clinical symptoms 
and exclusion of other causes of diarrhea (95). Severe CDI, in the form of pseudomembranous 
colitis, is accompanied by typical endoscopic and histological findings (96). However, in 
immunosuppressed patients, the macroscopic appearance of pseudomembranous colitis might 
not be readily evident (97).   
2.3.2 Cytomegalovirus  
Within one-year post-HSCT, the cumulative incidence of CMV disease has been estimated as 
approximately 5–6 %, with pneumonia, gastroenteritis, hepatitis, and retinitis as the most 
frequently observed manifestations (93, 98).  
The pre-HSCT serological CMV status of the donor and the recipient influences the risk of 
CMV disease, with the highest risk observed in a CMV seronegative donor to a CMV 
seropositive recipient (93, 99). Two different strategies have been developed to prevent the 
onset of CMV disease: prophylactic administration of anti-CMV drugs and a pre-emptive 
strategy. The latter includes CMV polymerase chain reaction (PCR)-based monitoring, once or 
twice weekly, and early treatment if CMV viremia is detected (100).  
Symptoms of CMV disease in the gastrointestinal tract include weight loss, dysphagia or 
odynophagia, nausea and vomiting, abdominal pain, diarrhea, and fever. Any of these 
symptoms, together CMV immunohistochemical staining, can serve as the basis for the 
diagnosis of CMV gastroenteritis (101).  
2.3.3 Post-transplant lymphoproliferative disease 
Post-transplant lymphoproliferative disease (PTLD) is a potentially life-threatening condition 
(102) that affects less than 2 % of HSCT patients (103). In pediatric HSCT patients, > 90 % of 
PTLD cases are associated with EBV and are of B-cell origin (104). EBV-induced 
transformation of B-cells occurs most frequently in a setting of impaired cellular immunity 
arising from ongoing immunosuppressive prophylaxis or treatment (104). Other risk factors for 
development of PTLD post-HSCT include HLA mismatch between the donor and recipient, 
RIC, a serological-based EBV-positive donor and an EBV-negative recipient, aGVHD grade 
2–4, and splenectomy performed pre-HSCT (102). In order to limit the risk of PTLD 
development post HSCT, PCR-based EBV-DNA viral load monitoring, at least once weekly 
for at least three months, is recommended (103). If EBV viremia is detected, preemptive 
treatment should be considered (103).  
The clinical presentation of PTLD most frequently includes lymphadenopathy, fever, and 
weight loss. Abdominal problems such as hepatosplenomegaly and gastrointestinal symptoms 
like diarrhea and hematochezia, have been observed in approximately every fifth patient with 
PTLD, based on a mixed-age HSCT population (105).  
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The final diagnosis of gastrointestinal PTLD relies on histopathology, including morphological 
assessment, immunophenotyping, and EBV-encoded RNA (EBER) in situ hybridization (106). 
Treatment options include reduction of immunosuppression, rituximab (anti-CD20 monoclonal 
antibodies), or chemotherapy (104).    
2.3.4 Typhlitis 
Typhlitis, or neutropenic enterocolitis, is a rare but life-threatening consequence of severe 
mucosal damage of the GI tract due to chemotherapy. Involvement of the cecum and right 
colon is seen in almost all affected individuals. Bowel wall perforation and sepsis may occur 
and require surgical resection and antibiotics (107). 
Taken together, the present evidence indicates that diarrhea during the post-HSCT period may 
have multiple causes. Infection of the GI tract needs to be considered early in the diagnostic 
procedure of individuals with clinically suspected GI-aGVHD, preferably before endoscopy is 
performed.  
 
2.4 RISK FACTORS FOR DEVELOPMENT OF ACUTE GRAFT-VERSUS-HOST 
DISEASE IN THE GASTROINTESTINAL TRACT 
Risk factors for the development of GI-aGVHD have not been studied in depth. However, 
addition of total body irradiation to the conditioning regimen (46), infection with enteric 
viruses, such as adeno- and norovirus, at the time of HSCT (108), and CDI (109) have been 
associated with an increased risk of subsequent development of GI-aGVHD. A common 
feature of these factors is that they have the potential to cause damage to the GI tract, thereby 
acting as initiators of the pathophysiological process of GI-aGVHD (Figure 2).  
Parenteral nutrition as the only feeding route (110) and administration of broad-spectrum 
antibiotics, such as ciprofloxacin, at the time of the transplantation (69) have also been 
associated with an increased risk GI-aGVHD. The mechanism of action that explains the 
association between antibiotics and GI-aGVHD has not been clarified. However, total 
parenteral nutrition as a risk factor for GI-aGVHD might be explained by an induction of tissue 
damage, including impaired barrier function and apoptosis, if the GI tract is not exposed to 
food (111, 112).   
2.4.1 Busulfan and cyclophosphamide conditioning, with or without the 
addition of melphalan   
Busulfan (Bu) and cyclophosphamide (Cy) conditioning was developed in 1983 by Santos et 
al. from the Johns Hopkins group as a way to avoid irradiation-induced conditioning-related 
toxicity (19). A third alkylating agent, melphalan (Mel), is sometimes added to the BuCy 
conditioning to further reduce the risk of graft failure and relapse (113). 
In the original BuCy regimen used by the Johns Hopkins group, Bu was administered orally. 
However, the pharmacokinetics of Bu is unpredictable and shows substantial interindividual 
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variation in bioavailability, particularly in children (114). Therefore, an increased risk of drug 
toxicity has been observed in individuals with high absorption of Bu and an increased risk of 
relapse and graft failure in those with low absorption (115). Management of the unpredictable 
pharmacokinetics requires either intravenous administration of Bu or therapeutic drug 
monitoring followed by dose adjustments in patients treated with oral administration (19). 
The main toxic manifestations of BuCy conditioning include sinusoidal obstructive syndrome 
(116), hemorrhagic cystitis (117), and drug toxicity affecting the gastrointestinal tract, the 
kidneys, and the central nervous system (118). Furthermore, the addition of Mel to BuCy has 
been found to increase the risk of aGVHD (119). However, whether the addition of Mel to the 
BuCy conditioning increases the risk of GI-aGVHD is not known. 
 
2.5 DIAGNOSTIC OF ACUTE GRAFT-VERSUS-HOST DISEASE IN THE 
GASTROINTESTINAL TRACT  
Acute GI-GVHD is primarily a symptom-based diagnosis. However, symptoms due to GI-
aGVHD are nonspecific. Additional diagnostic tools to support or confirm the GI-aGVHD 
diagnosis are therefore of clinical importance. The MAGIC consensus GVHD research 
guidelines state that histopathological confirmation of GI-GVHD is the most important 
available diagnostic test for attributing gastrointestinal symptoms to GI-aGVHD (7) . However, 
in children (below 18 years of age), in contrast to adults, esophagogastroduodenoscopy (EGD) 
and colonoscopy, with or without ileal intubation, should be performed under general 
anesthesia, either in an operating theater or endoscopic procedure room (120, 121). Thus, 
endoscopy in children is a logistically complex and time-consuming procedure that may 
interfere with prompt management (122). Consequently, the potential clinical value of 
diagnostic tools other than histopathology might be of particular importance in children.    
2.5.1 Imaging  
Findings on computed tomography (CT) (123), magnetic resonance imaging (MRI) (124), and 
transabdominal ultrasonography (US) (125) in individuals with histopathologically proven GI-
GVHD have been associated with non-specific findings, such as bowel wall thickening and 
abnormal mucosal enhancement. Thus, CT, MRI, and US add nonspecific information of less 
clinical importance to support the GI-aGVHD diagnosis.  
2.5.2 Plasma and fecal biomarkers 
The antimicrobial peptide, Reg-3-α, produced by the GI tract epithelium has been evaluated as 
a biomarker of GI-GVHD (126). Significantly higher plasma levels of Reg-3-α were observed 
in individuals with histopathology-based lower GI tract GVHD versus individuals without 
GVHD or solely with skin GVHD. The highest level of Reg-3-α was found in individuals with 
severe GI-GVHD (126). However, confirmatory studies are needed before Reg-3-α can be 
incorporated into standard clinical practice (80). 
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Calprotectin is a protein that is mainly released to the bowel lumen from neutrophils during GI 
tract inflammation. Analysis of fecal calprotectin is a routine test in the context of inflammatory 
bowel disease (IBD); during the primary diagnostic workup, to evaluate IBD treatment 
response and, to identify IBD flare-up. Elevated fecal calprotectin levels have also been found 
in GI-aGVHD (127, 128). Furthermore, a  positive correlation has been observed between 
levels of fecal calprotectin and disease severity grade of GI-aGVHD (127), However, the 
ability of fecal calprotectin to differentiate between GI-aGVHD and non-GI-aGVHD causes of 
GI tract symptoms has not been studied in depth (129). In summary, fecal calprotectin shows 
promising results as a diagnostic tool for GI-aGVHD, but its specificity needs further 
clarification.  
2.5.3 Macroscopic appearance of the GI tract mucosa 
In endoscopies performed to confirm symptom-based GI-aGVHD, histopathology reveals GI-
GVHD in approximately every second endoscopic occasion with a normal macroscopic 
appearance of the GI tract mucosa (130, 131). Therefore, endoscopy, solely based on visual 
inspection of the GI tract mucosa, has low additive value in the diagnostics of GI-aGVHD.   
 
2.6 HISTOPATHOLOGY-BASED DIAGNOSIS OF ACUTE GRAFT-VERSUS-
HOST DISEASE IN THE GASTROINTESTINAL TRACT 
Abnormal histology related to GI-GVHD is primarily located in the crypts of the GI tract 
epithelium, which are in an area with a high proportion of intestinal stem cells and Paneth cells.  
The histological hallmark of GI-GVHD is crypt apoptosis (8, 132). Other histological findings 
include crypt destruction, mucosal denudation, reduced numbers of Paneth cells in the small 
intestine, and sparse infiltration of lymphocytes and eosinophils in the lamina propria (74, 
133). 
2.6.1 Minimal criterion of histopathology-based GI-aGVHD 
The minimal histopathological criterion of GI-GVHD has not been established (8). However, 
the NIH (2005/2014) defines the histopathological threshold of GI-GVHD as detection of at 
least one apoptotic body in a crypt per biopsy piece (8, 88).  
Nevertheless, apoptosis is not a unique histological finding of GI-GVHD, and particularly 
not findings of less than one apoptotic body per biopsy piece (134, 135). Therefore, to 
increase the diagnostic specificity, more than one apoptotic body per biopsy piece, have been 
proposed as a minimal criterion (136-138). However, due to the overall trade-off between 
sensitivity and specificity, increased number of apoptotic events needed for the GI-GVHD 
diagnosis may decrease the diagnostic sensitivity, thereby potentially increasing the risk that 
clinically relevant cases of GI-GVHD will remain undetected. 
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  Figure 3: Normal colonic mucosal histology 
 
2.6.2 Histopathology-based disease severity grading  
Histopathology-based disease severity scoring of GI-GVHD is most often based on the four-
tiered scoring system described by Lerner et al. (139); 
• Grade 1: Apoptotic epithelial cells, without crypt loss (Figure 4) 
• Grade 2: Apoptotic epithelial cells and individual crypt loss or crypt destruction 
(Figure 5) 
• Grade 3: Apoptotic epithelial cells and i) contiguous areas of multiple crypt loss or 
crypt destructions, and/or, ii) focal mucosa denudation, and/or iii) focal ulceration 
• Grade 4: Diffuse denudation of the epithelium or ulceration. Apoptotic epithelial 
cells, not always possible to detect (Figure 6)    
Grading of the disease severity of GI-GVHD based on histopathology is somewhat 
controversial. However, the histopathology-based disease severity may add prognostic 
information of clinical value. For example, Lerner grades 3–4 versus grade 1-2, have been 
associated with an increased risk of SR-GI-aGVHD (140) and reduced probability of survival 
(135).  
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    Figure 4. Apoptotic bodies in colon, indicated with arrows (Lerner grade 1) 
 
 
 
    Figure 5. Lerner grade 2 with apoptotic epithelial cells and a single crypt destruction 
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Figure 6. Lerner grade 4 with complete destruction of the colonic mucosa including 
denudation of the epithelium 
 
2.6.3 False negative interpretation of histopathology-based GI-GVHD 
GI-GVHD may remain undetected during the histopathological assessment due to the 
following (8, 133):  
o Small biopsy pieces, insufficient to detect infrequent apoptotic bodies 
o Biopsy sampling performed within an ulcer, rather than in the transitional area to intact 
mucosa 
o Ongoing anti-GI-GVHD treatment at the time of biopsy sampling 
o Suboptimal processed and stained biopsy slides 
o Serial sections that do not go down to the base of the crypts  
o Suboptimal extent of the endoscopic procedure   
o Interobserver disagreement between different pathologists  
2.6.3.1 Choice of endoscopic procedure 
Sigmoidoscopy, in contrast to EGD and colonoscopy/ileocolonoscopy, represents an 
endoscopic procedure that might be performed under minimal sedation in children (141-143). 
Thus, evaluation of the diagnostic reliability of the GI-GVHD diagnosis based on biopsies from 
the rectosigmoid area is important.  
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Four previous pediatric studies (130, 144-146) have evaluated sigmoidoscopy as a potential 
first choice endoscopic procedure in children with symptom-based GI-aGVHD. Two of four 
studies were based on biopsy sampling from full upper and lower endoscopy (144, 145). In 
these studies, nine of 13 (69 %) and 13 of 18 (72 %) endoscopic occasions with histopathology-
based GI-GVHD anywhere in GI tract were simultaneously detectable in biopsies from the 
rectosigmoid area (144, 145).  
In the remaining two studies, the sensitivity of the histopathology-based GI-GVHD diagnosis 
was compared, based on biopsy sampling from the rectosigmoid area versus the upper GI tract 
(130, 146). In one of these studies, all (n=9) children with a histopathology-confirmed GI-
GVHD diagnosis in biopsies from the upper endoscopic procedure were confirmed in biopsies 
from the rectosigmoid area (146). In the other study (n=22), the sensitivity for the GI-GVHD 
diagnosis based on biopsies from the rectosigmoid area was 77 % (130).  
Taken together, it remains unclear, due to limited sample sizes in previous pediatric studies, if 
sigmoidoscopy can be recommended as preferred first choice of endoscopic procedure in 
children with clinically suspected GI-aGVHD (130, 144-146).  
2.6.3.2 Interobserver disagreement  
In a histopathology-based study performed by five pathologists using 33 biopsies with GI-
GVHD, full agreement of the GI-GVHD diagnosis among the pathologists was observed in 23 
biopsies (70 %) (132). The corresponding figure of agreement for grading of GI-GVHD in 
accordance to Lerner et al. was 48 %. In another adult patient study that included 217 
endoscopic occasions performed due to clinically suspected GI-GVHD, the clinical standard 
histopathological assessment (CSHA) confirmed the GI-aGVHD diagnosis in 166 (53 %) 
endoscopic occasions (134). In a subsequent retrospective, independent, histopathological 
assessment (RIHA) based on the NIH 2014 criteria, the corresponding result was 173/217 (80 
%) (134). None of these previously mentioned studies included a detailed analysis of the 
potential clinical consequences related to the differences in the assessments (132, 134).  
2.6.4 False positive interpretation of histopathology-based GI-GVHD 
False positive interpretation of histopathology-based GI-GVHD may reflect apoptosis-
inducing factors other than GI-GVHD (Table 3), as well as interobserver disagreement.   
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2.6.5 Evaluation of diagnostic tools in the absence of diagnostic reference 
standard 
A reference standard is required for assessment of whether the NIH 2014 criteria or other 
thresholds for the GI-aGVHD diagnosis add information that increases or decreases the 
uncertainty of the GI-aGVHD diagnosis. However, no such reference standard has been 
established for histopathology-based GI-GVHD (8). Without a diagnostic reference standard, 
the clinical evaluation of a diagnostic test needs to be based on other markers that can be used 
to evaluate the post-test versus pre-test probability of a correct diagnosis (163). These markers 
may include primary disease endpoints, such as therapeutic decisions, or other aspects of 
patient management or clinical outcome, such as survival (163).  
Table 3. Potential apoptosis inducing factors, that may mimic histopathology-based 
gastrointestinal GVHD diagnosis 
Histopathological mimic Main “target” region 
of the GI tract 
   Experimental  
   model 
 References 
    
CMV  Entire GI tract Human Karamchandani 2018 
(147) 
Salmonella, Shigella, 
Yersinia, Campylobacter spp. 
Rectum to terminal ileum Human and 
mice 
Navarre 2000 (148),  
Bucker 2018 (149) 
Norovirus  Terminal ileum to 
duodenum 
Human Troeger 2009 (150) 
Rotavirus  Terminal ileum to 
duodenum 
Human Chaibi 2005 (151) 
Adenovirus Entire GI-tract Human  Westerhoff 2017 (107) 
Clostridium difficile  Rectum to caecum Mice Chumbler 2016 (152) 
Helicobacter pylori Gastric antrum and corpus Human Moss 2001 (153) 
Conditioning regimen    Entire GI tract Human Epstein 1980 (154),  
Jalili-Firoozinezhad 
2018 (155) 
Mycophenolate mofetil  Entire GI tract Human Nguyen 2009 (156), 
Papdimitriou 2003 
(157)  
Tacrolimus  Unknown  Mice Yoshino 2010 (158), 
Fujino 2007 (159) 
Total Parenteral 
Nutrition/no enteral 
nutrition 
Unknown Mice Cao 2000 (160), 
Wildhaber2002 (112) 
Non-steroidal anti-
inflammatory drugs  
Entire GI tract Human Parfitt 2007 (161) 
Bowel preparation Rectum to caecum Human Westerhoff 2017 (107) 
Proton pump inhibitor Gastric antrum Human Welch 2006 (162) 
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2.6.6 Potential clinical consequences of over- and under-diagnosis of GI-
GVHD 
An association between non-detected histopathology-based GI-GVHD diagnosis and an 
increased risk of mortality is not yet known. Similarly, whether undetected GI-GVHD 
increases the risk of potentially avoidable re-endoscopies remains to be established. The latter 
might of greater clinical relevance in children than adults since i) an increasing number of 
publications have reported that repeated exposure to general anesthesia in children, is harmful 
(164, 165), at least in children below the age of three years (166); ii) biopsy sampling–induced 
intraduodenal hematoma has been reported to occur more frequently in children with 
endoscopy performed to confirm clinically suspected GI-GVHD compared to other medical 
indications (167, 168).  
Conversely, overdiagnosis of GI-GVHD may increase the risk of unnecessary treatment with 
immunosuppressive drugs, thereby increasing the risk of potential avoidable side effects, such 
as viral infections (169), infectious related death (170), and other drug-associated side effects 
(171).  
2.6.7 Reporting final histopathological diagnosis in accordance with the 
NIH 
To facilitate a comparison of the outcome between different studies within the field of 
histopathology-based GI-GVHD, the NIH recommends standardized reporting of the final 
histopathological diagnosis, based on the following categories: not GVHD, possible GVHD, 
or likely GVHD (8). The category likely GVHD represents a merged group, previously 
described as consistent and definite GVHD (88).  
In possible GI-GVHD, evidence of GVHD has been found but other explanations of the 
histopathology picture are possible, such as CMV enteritis or drug-induced mucosal reaction 
(Table 3). Likely GI-GVHD includes clear histopathology-based evidence of GI-GVHD, 
ranging from minimal to marked GI tract injury (8).  
Based on a study including adult HSCT patients with endoscopy-guided histopathological 
assessment performed due to clinically suspected GI-GVHD, the three-year overall survival 
was 64 % in individuals classified as possible GI-GVHD and 31 % in those classified as 
likely GI-GVHD (135). The overall survival in individuals classified as possible GI-GVHD, 
did not differ compared with those without histopathology-based GI-GVHD. Based on these 
findings, the authors of the study proposed to merge those with histopathology-based possible 
GI-GVHD and those without signs of GI-GVHD into one group (135). 
2.6.8 Final diagnosis in clinical practice  
In daily clinical practice, the final GI-aGVHD diagnosis represents an aggregated interpretation 
of different clinical data, such as:  
• Symptoms 
• Occurrence of risk factors for the development of GI-aGVHD 
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• Histopathological findings 
• Occurrence of infections or treatment with drugs that may cause GI-aGVHD-like 
symptoms or may induce GI tract apoptosis 
• Simultaneous manifestations of aGVHD in organs other than the GI tract 
• Response to anti-GI-GVHD treatment, if that has been started before the final 
diagnosis has been established 
The attributed value of endoscopy-guided histopathological assessment in daily clinical 
management of adult patients with suspicion of GI-aGVHD was highlighted in a survey of 
current clinical practice in diagnosis and treatment of aGVHD (172). In that study, 30 of 34 
(88 %) European HSCT centers reported that they would perform endoscopy with biopsy 
sampling before starting anti-GI-GVHD treatment in a patient presenting with diarrhea and 
decreased oral intake after HSCT (172). Corresponding pediatric studies are lacking.  
 
2.7 TREATMENT CHANGES BASED ON HISTOPATHOLOGY FINDINGS 
One previous study has evaluated the frequency of treatment changes prompted by results from 
histopathological assessment, in children with symptom-based GI-aGVHD (173). In that study, 
40 % of the participants were on anti-GI-GVHD treatment at the time of the endoscopy. Despite 
that, only initiation and dose escalating of anti-GI-GVHD drugs were included in the study-
specific definition of treatment changes. Thus, neither a dose reduction or withdrawal of anti 
GI-GVHD drugs nor treatment modifications due to finding an alternative diagnosis were 
classified as treatment changes.  
In summary, no previous pediatric study has evaluated the overall frequency of treatment 
changes based on endoscopy-guided histopathological assessment performed to confirm 
symptom-based GI-aGVHD. 
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3 OBJECTIVES AND AIMS 
 
3.1  OVERALL OBJECTIVES 
• To study the influence of two different conditioning regimens on the incidence of GI-
aGVHD in HSCT-treated children  
• To evaluate clinical aspects of the currently recommended diagnostic approach to GI-
aGVHD, i.e., endoscopy-guided histopathological assessment, applied to pediatric 
HSCT patients 
 
3.2  SPECIFIC AIMS 
o To evaluate if addition of Mel to the BuCy conditioning regimen increases the 
incidence of GI-aGVHD within 100 days post-HSCT in children suffering from 
juvenile myelomonocytic leukemia (JMML) or myelodysplastic syndrome (MDS) 
(paper I)  
 
o To evaluate the frequency of treatment changes: initiation, dose escalation, tapering, or 
withdrawal of anti-GI-GVHD drugs and other changes to medication based on 
endoscopy-guided histopathological assessment performed to confirm symptom-based 
GI-aGVHD in children (paper II) 
 
o To evaluate the frequency of histopathological disagreement of the GI-GVHD 
diagnosis between CSHA and NIH 2014-based RIHA performed blinded by one 
pathologist (paper III) 
 
o To assess the risk of subsequent re-endoscopy within one-year post-HSCT and of death 
within two years post-HSCT as a potential consequence of mismatch of the GI-GVHD 
diagnosis between CSHA and RIHA (paper III)  
 
o To evaluate if biopsies from the rectosigmoid area versus from the rest of the 
colon/ileocolon, with or without biopsies from simultaneous upper endoscopy, are 
equally reliable for establishing a histopathology-based GI-GVHD diagnosis (paper 
IV) 
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4 PATIENTS AND METHODS 
 
4.1  PATIENTS 
4.1.1 Patients: paper I 
This was a single center study carried out in children <18 years of age at Karolinska University 
Hospital Huddinge. The study enrolled all children with HSCT performed during 2000–2010 
with the underlying diagnoses of JMML and MDS and with a conditioning regimen of BuCy, 
with or without addition of Mel. Children with JMML and MDS were chosen since these 
diagnoses proceed directly to HSCT when the diagnosis has been established (174, 175). Thus, 
the patients were minimally exposed to chemotherapy prior to HSCT, thereby avoiding GI 
toxicity that may have influenced the outcome.  
A total of 26 patients were identified. However, one child with JMML died prior to neutrophil 
engraftment, thus, before fulfilling the prerequisite for development of aGVHD, and was 
therefore excluded. 
4.1.2 Patients: paper II-IV 
Paper II-IV enrolled patients from all pediatric HSCT centers in Sweden (Gothenburg, Lund, 
Stockholm, Uppsala). The participants were identified via hospital record databases, local 
registries of HSCT-treated children, and databases for pathology.  
A primary study population was collected that fulfilled the following inclusion criteria: i) age 
below 18 years at time of HSCT, ii) HSCT performed during 2000–2012, and iii) endoscopy 
with biopsy sampling performed to confirm symptom-based GI-aGVHD within the first year 
post-HSCT (Figure 7). 
Based on the study-specific inclusion criteria, samples were drawn from the primary study 
population to each study. These study-specific inclusion criteria were: 
Study II: Available histopathology reports 
Study III: Available histopathology reports and biopsy slides for RIHA 
Study IV: Available biopsy slides for RIHA. Lower endoscopy performed with biopsy 
sampling from at least; the rectosigmoid area, and from the area proximal of the left colonic 
flexure to the terminal ileum 
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Figure 7. Recruitment of participants to study II-IV 
 
4.2  METHODS 
4.2.1 Methods: paper I 
This was a retrospective descriptive cohort study based on hospital record data. The study 
covered day 0–100 post-HSCT. The GI-aGVHD diagnosis was symptom-based and defined 
and staged by the modified Glucksberg criteria (31). The frequency of GI-aGVHD stages II–
IV and other clinical data were compared between children with BuCyMel versus BuCy 
conditioning.  
  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 
 
 
 																																																														
 
 
 
	
HSCT	in	children		<18	years	of	age,	between	2000-2012,	in	Sweden	
n=607	children	
Study	II	specific	inclusion	criteria	not	fulfilled		n=6	EO	
Study	III	specific	inclusion	criteria	not	fulfilled		n=5	EO	
Study	IV	specific	inclusion	criteria	not	fulfilled	
	n=46	EO	
	Available	histopathology	reports		
	
	
Endoscopy-guided		biopsy	sampling	to	confirm	
symptom-based	GI-aGVHD	within	one	year	post-HSCT	
n=74	children,	97	endoscopic	occasions	(EO)	
	Primary	inclusion	criteria	not	fulfilled				n=533	children	
	Available	histopathology	reports	and	biopsy	slides		
	
Biopsy	sampling	from	at	least;	the	rectosigmoid	area,	and	from	the	area	proximal	of	the	left	colonic	flexure	to	the	terminal	ileum	
	
	Included	in	study	II		
n=68	children,	91	EO	
	
	Included	in	Study	III		
n=70	children,	92	EO	
	
	Included	in	Study	IV		
n=44	children,	51	EO	
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4.2.2 Methods: paper II 
This was a retrospective cohort study based on data from histopathology reports and hospital 
records. Data collection from the hospital records included clinical background information, 
changes in drug treatment prompted by histopathological findings, two-year post-HSCT 
survival, and, in those who died, the cause of death. The endoscopic occasions were divided 
dichotomous, based on a treatment change or not, guided by the histopathology reports.  
Treatment changes was defined as initiation, dose escalation, dose reduction or withdrawal of 
anti-GI-GVHD treatment, and other changes to medication, based on histopathological 
findings. If data on treatment changes in the medical records were lacking, classification as a 
treatment change was only done if the change was made in agreement with the histopathology 
report and was performed subsequent to, but not later than, 14 days after the histopathology 
report was available.  
Due to non-standardized reporting, all endoscopic occasions with a histopathology report 
indicating a suggestion of GI-GVHD were classified as GI-GVHD. Thus, phrases in the 
histopathology reports such as “possible,” “slight,” and “minimal” were judged as GI-GVHD.   
4.2.3 Methods: paper III 
This was a retrospective cohort study. The study was based on data from histopathology 
reports, hospital records, and results from RIHA. The RIHA process is described in paragraph 
4.2.5. Histopathological diagnoses established in the CSHA were collected from the 
histopathology reports. Due to non-standardized reporting, all endoscopic occasions with a 
histopathology report indicating a suggestion of GI-GVHD were classified as GI-GVHD.  
The results from CSHA and RIHA were categorized as GI-GVHD (+) or non-GI-GVHD (-). 
Based on the results from the CSHA and the RIHA, four subgroups were defined: endoscopic 
occasions with detection of GI-GVHD in the CSHA and the RIHA (+ +); GI-GVHD solely 
detected in the RIHA (- +); GI-GVHD detected in the CSHA but reclassified as non-GI-GVHD 
in the RIHA (+ -); non-GI-GVHD detected in both readings (- -).  
Diagnostic disagreement of histopathology-based GI-GVHD diagnosis was based on the 
subgroup (+ -) and (- +). The analysis of the risk of a subsequent re-endoscopy within one year 
was based on subgroup affinity (+ +, - +, + -, - -) of the endoscopic occasion that preceded the 
re-endoscopy. These subgroups were also the basis for the analysis of death within two years 
post-HSCT. Differences in frequencies of histopathology-based disease severity scores of acute 
and overlap GI-GVHD were based on endoscopic occasions with GI-GVHD solely detected in 
the RIHA (- +) versus corresponding cases detected in both assessments (+ +).  
4.2.4 Methods: paper IV 
This was a retrospective study based on results from re-evaluation (hereinafter referred to as 
RIHA) (Paragraph 4.2.5), and hospital record data. The study was based on the assumption that 
a finding of GI-GVHD during the RIHA represented a true positive result. 
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Sensitivity and disagreement analyses were performed. In the disagreement analysis, the results 
from the RIHA, based on biopsies from different areas of the GI tract were merged into the 
following groups: i) the rectosigmoid area, ii) the rest of the colon and the terminal ileum (when 
intubated), and iii) the upper GI tract. The distribution within the GI tract of alternative 
histopathology-based diagnoses was also based on these groups. In the sensitivity analysis, the 
results from the RIHA were merged into groups representing different endoscopic procedures: 
sigmoidoscopy (rectosigmoid area), colonoscopy (the rectum to the cecum), ileocolonoscopy 
(the rectum to the terminal ileum), and EGD (the duodenum to the esophagus).  
4.2.5 Common methodology – paper III and IV 
The RIHA in paper III and IV was performed in an identical way; blinded, protocol-based, by 
one pathologist (A.S.), based on slides with good-quality hematoxylin and eosin and 
immunohistochemical cytomegalovirus (CMV) staining. The pathologist used the NIH 
2005/NIH 2014 criteria for minimal histological threshold of GI-aGVHD; that is, finding of at 
least one apoptotic body in a crypt per biopsy piece (8). In cases with histopathology-based 
acute GI-GVHD or overlap GI-GVHD, histological severity grading was performed in 
accordance with Lerner et al. (139).  
In line with NIH 2005 guidelines, the final RIHA-based GI-GVHD diagnosis in paper IV was 
reported as possible, consistent, or definite GI-GVHD (88), and in paper III as possible or 
likely, in accordance with the 2014 criteria (8). All endoscopic occasions in paper III and IV 
with histological findings indicating GI-GVHD, but other explanations were possible; thus, 
possible GI-GVHD was classified as “normal or non-specific findings.” Only endoscopic 
occasions defined as consistent/definite GI-GVHD (88) or likely GI-GVHD (8) were judged as 
GI-GVHD.  
During the RIHA, all cases were assessed for CMV as a cause of apoptosis. Separate from the 
RIHA, the influence of factors other than CMV that may induce apoptosis were evaluated as 
potential mimickers of GI-GVHD. 
4.2.6 Definitions  
Paper 1:  Prolonged regimen-related diarrhea: Three or more loose or liquid stools per 
day, without positive infectious disease tests from the feces and with onset during the 
administration of the conditioning regimen and with duration beyond the time point of 
neutrophil engraftment. 
  Hemorrhagic cystitis: Occurrence of microscopic or gross hematuria with 
negative urine bacterial culture (176). 
 Sinusoidal obstruction syndrome: The diagnosis of sinusoidal obstruction 
syndrome was based on the Jones criteria; that is, bilirubin >34 mM with onset before day 21 
post-HSCT together with at least two of the following: i) hepatomegaly, ii) ascites, iii) 5% or 
greater weight gain (177). 
  37 
Paper 2-4: Endoscopic occasion: Any single diagnostic endoscopy procedure, regardless if 
solely upper or lower endoscopy has been performed or if the occasion included combined 
upper and lower procedures. 
Paper 3-4:  Colonoscopy/ileocolonoscopy: Endoscopy-guided biopsy sampling performed 
from the area proximal to left colonic flexure to the caecum or terminal ileum (when intubated). 
4.2.7 Statistics 
Endoscopic occasions were the main unit for analyses performed in paper II-IV. If serial 
endoscopic occasions were performed, each occasion was considered independent in the 
statistical analyses performed in paper II-III. 
Categorical variables were summarized and presented as frequencies and percentages, and 
numerical variables as mean, median, standard deviation (SD), and interquartile range (IQR), 
as appropriate. Fisher's exact was used to compare categorical data between subgroups in the 
studies. For normally distributed numerical data, the corresponding method was the t-test, and 
Mann-Whitney U test for data without a normal distribution. These calculations were 
performed with the exclusion of missing data. The disagreement analyses in paper III-IV were 
based on McNemar’s test. For the comparison of the probability of survival between subgroups 
in paper II-III and the probability of a subsequent re-endoscopy in paper III, a stratified 
proportional Cox regression analysis was performed. These analyses were based on endoscopic 
occasions and each endoscopy, if serial procedures were performed, contributed to the survival 
function and probability of a subsequent re-endoscopy until the time point of the next 
endoscopic occasion, but was thereafter censored. Statistical significance was defined as 
p<0.05. 
4.2.8 Ethics 
All studies included in this thesis were conducted in accordance with the Declaration of 
Helsinki and were approved by the Swedish Ethical Review Authority, Sweden. 
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5 RESULTS AND DISCUSSION 
 
5.1  RESULTS AND DISCUSSION PAPER I 
Twenty-five children were enrolled, seventeen conditioned with BuCyMel and eight with 
BuCy.  
Key finding: 
• Forty-seven percent (8/17) of the children that received addition of Mel to the BuCy 
conditioning, versus none (0/8) in the BuCy group, developed symptom-based GI-
aGVHD (stages 2-4) (p<0.05) 
Other findings: 
o Overall survival, independently of time post-HSCT, was 53 % (9/17) in the BuCyMel 
group and 63 % (5/8) in the BuCy group 
o Relapse of the underlying diagnosis for HSCT occurred in four patients, two in the 
BuCyMel group and two in the BuCy group 
o Toxic manifestations, i.e., hemorrhagic cystitis, prolonged regimen-related diarrhea 
and sinusoidal obstruction syndrome, were observed in 47 % (8/17), 35 % (6/17), and 
6 % (1/17), respectively, in the BuCyMel group. None of the children in the BuCy 
group developed these manifestations. 
The rationale of adding Mel to the BuCy conditioning regimen in children has been to reduce 
the risk of relapse (113). However, Mel has also been associated with gastrointestinal toxicity 
(178), thereby potentially acting as initiator of aGVHD (43, 44, 179).  
The results in paper I indicate that the addition of Mel to the BuCy conditioning increases the 
risk of regimen-related toxicity and the risk of GI-aGVHD (stages 2-4). However, the role of 
adding Mel to the BuCy conditioning regimen needs to be considered in a broader context. A 
previous study that included children with acute myeloid leukemia showed that BuCyMel, 
compared to BuCy conditioning, was associated with a higher probability of survival, a lower 
relapse rate, and a higher risk of severe aGVHD (grade 3–4) (119). In that study, the aGVHD 
diagnosis was symptom-based, thus less specific (7), and no specification was given of the 
incidence of aGVHD in each affected organ system for the BuCy and the BuCyMel groups 
(119).  
Due to the small sample size in study I, the probability of survival and risk of relapse needs to 
be further clarified. Preferably, that type of study would have a prospective randomized design 
and would include endoscopy with histopathological assessment for all individuals developing 
clinically suspected GI-aGVHD.  
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5.2  RESULTS AND DISCUSSION PAPER II 
Ninety-one endoscopic occasions performed in sixty-eight children were enrolled. Twenty-
three procedures were re-endoscopies. Anti-GI-GVHD treatment at the time of the endoscopic 
occasion was ongoing in 71% (65/91) and not ongoing in 29 % (26/91).  
Key findings: 
• Treatment changes in response to histopathology reports was observed in 48 % (44/91) 
• In 18 % (12/65) with start of anti-GI-GVHD treatment pre-endoscopically, no medical 
causes were found justifying that treatment  
• The two-year overall post-HSCT survival was 62 %, without difference between the 
treatment changes versus the unchanged treatment group (Hazard ratio 1.28, 95% CI 
0.60-2.70, p=0.524) 
Other findings: 
o The negative prognostic factor, grossly bloody diarrhea, was present in 27 % (12/44) 
in the treatment change group and in 9 % (4/47) in the unchanged treatment group 
(p=0.003), at the time of endoscopy 
In paper II, almost every second endoscopic occasion performed to confirm symptom-based 
GI-aGVHD was followed by treatment changes based on the histopathology assessment. The 
corresponding figure was 45 % in an adult patient study, using a similar definition of treatment 
change as in paper II (180). In the only previous pediatric study, 30 % of the endoscopic 
occasions were followed by initiation or dose escalation of anti-GI-GVHD drugs (173). These 
results support that treatment decisions in daily clinical practice are influenced by endoscopy-
guided histopathological assessment.   
In almost every fifth endoscopic occasion where anti-GI-GVHD treatment was started pre-
endoscopically, no histopathological evidence of GI-GVHD or other medical causes were 
found to justify that treatment. Instead, in these endoscopic occasions, the anti-GI-GVHD 
treatment exposed children unnecessarily to the risk of avoidable side effects associated with 
immunosuppressive drugs (169-171).        
In paper II, no difference was found in the overall two-year post-HSCT survival in individuals 
in the treatment change group compared with individuals in the unchanged treatment group. 
This result was unexpected since: i) the negative prognostic factor, grossly bloody diarrhea 
(181, 182), was more frequently observed in the treatment change group and, ii) all individuals 
in the study cohort exposed to overtreatment or undertreatment with anti-GI-GVHD agents 
pre-endoscopically belonged, by definition, to the treatment change group. Thus, the treatment 
change group possibly represents individuals in study II with less favorable survival chances 
post-HSCT. Based on that, the similar two-year overall survival in the treatment change group 
and the unchanged treatment group, may imply a positive influence of histopathology-guided 
treatment changes on survival in children with clinically suspected GI-GVHD. 
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5.3  RESULTS AND DISCUSSION PAPER III 
Ninety-two endoscopic occasions performed in seventy children were enrolled. Twenty-two 
procedures were re-endoscopies. In the analyses of risk of a subsequent re-endoscopy within 
one-year and of death within two-year post-HSCT, the subgroup (+ -) was excluded due to its 
small sample size (three endoscopic occasions). 
Key findings: 
• In the NIH-based RIHA, histopathology-based GI-GVHD diagnosis was established in 
67 of 92 (73 %) of the endoscopic occasions, and in the CSHA, in 50 of 92 (54 %) 
(p=0.014) 
• In 94 % (47/50), the RIHA confirmed the GI-GVHD diagnosis established in the CSHA 
(+ +). The corresponding result for non-GI-GVHD (- -) was 52 % (22/42) 
• Diagnostic disagreement, i.e., GI-GVHD solely detected in the RIHA (- +) or GI-
GVHD detected in the CSHA but not in the RIHA (+ -), was observed in 48 % (20/42) 
and 6 % (3/50), respectively (McNemar´s test, p=0.0008) 
• The risk of a subsequent re-endoscopy within one-year post-HSCT was higher in 
endoscopic occasions with GI-GVHD solely detected in the RIHA (- +) than if non-GI-
GVHD was detected in both assessments (- -) (P=0.005) 
Other findings: 
o The results were not influenced by factors, other than GI-GVHD, with the potential to 
induce apoptosis in the GI tract 
o GI-GVHD solely detected in the RIHA, and consequently undetected in the CSHA (- 
+), had no impact on the probability of survival 
o Histopathology-based severity grade 1 was observed in 70 % (14/20) of the endoscopic 
occasions with GI-GVHD solely detected in the RIHA (- +) and in 34 % (15/45) of the 
endoscopic occasions with GI-GVHD detected in both assessments (+ +) (p=0.008) 
In paper III, the GI-GVHD diagnosis was more frequently established in the NIH 2014-based 
RIHA versus CSHA. Furthermore, the assessment performed by the pathologist in the RIHA 
showed no indication of being misled by drugs or infectious agents with the potential to induce 
apoptosis, thereby mimicking the histological pattern of GI-GVHD.  
Two of three cases with non-detected GI-GVHD in the CSHA but detected in the RIHA (- +) 
had histological severity grade 1, i.e., solely finding crypt apoptosis (139). This result indicates 
that some pathologists performing the CSHA required a higher number of apoptotic bodies to 
establish the GI-GVHD diagnosis versus the minimal criteria for histopathology-based GI-
GVHD by the NIH 2014 (8).    
The MAGIC consensus GVHD research guidelines point out histopathology as the most 
important diagnostic test for attributing gastrointestinal symptoms to GI-GVHD (7). However, 
the clinical usefulness of that statement is negatively influenced by the lack of consensus 
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regarding minimal criteria of the histopathology-based GI-GVHD diagnosis. In the absence of 
a diagnostic reference standard, other markers to evaluate the post-test versus pre-test 
probability of a correct diagnosis are needed (163). In paper III, GI-GVHD solely detected in 
the RIHA (- +) did not influence the probability of two-year post-HSCT survival. However, 
the risk of a subsequent re-endoscopy was higher if GI-GVHD was detected in the RIHA but 
not in the CSHA (- +) versus if GI-GVHD was not detected in any of the assessment methods 
(- -). The increased risk of a subsequent re-endoscopy in the - + subgroup indicated a potential 
advantage of using the NIH 2014 criteria in children with symptom-based GI-aGVHD but 
without a histopathology-based confirmation in the CSHA.  
 
5.4  RESULTS AND DISCUSSION PAPER IV 
Fifty-one endoscopic occasions performed in 44 children were enrolled. 
Key findings: 
• In 76 % (39/51) of the endoscopic occasions, a histopathology-based GI-GVHD 
diagnosis was established  
• The sensitivity for the GI-GVHD diagnosis was 85 % for biopsies from the 
rectosigmoid area  
• The sensitivity of histopathology-based GI-GVHD diagnosis in combined biopsy 
sampling from the rectosigmoid area and the upper GI tract was 97 %, which was 
similar to biopsies collected from rectosigmoid-ileocolonic areas 
• McNemar’s test revealed a difference between non-detected histopathology-based GI-
GVHD diagnosis in biopsies collected from the rectosigmoid area versus detected 
elsewhere in the GI tract (p=0.031)   
Other findings: 
o Immunohistochemical detection of CMV was the most frequently observed alternative 
diagnosis found in 14 % (7/51) of the endoscopic occasions 
o In 6/7 cases with immunohistochemical detection of CMV, concomitant GI-GVHD 
was present 
o CMV had a patchy distribution in the GI tract, with 2/7 detected in biopsies from the 
rectosigmoid area. The corresponding figure was 6/7 in merged analysis of biopsies 
from the rectosigmoid and the upper GI tract    
Sigmoidoscopy represents a straightforward endoscopic procedure that, in a pediatric 
population, might be performed under minimal sedation (141-143). Thus, sigmoidoscopy has 
the potential to be performed as soon as GI symptoms appears, potentially allowing early 
distinction between GI-GVHD and other GI tract conditions that may require different 
treatment.  
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In paper IV, biopsy sampling from the rectosigmoid area detected 85 % of all cases with 
histopathology-based GI-GVHD diagnosis. Similar results have been observed in previous 
studies (131, 144). However, paper 4 is the first pediatric study to report a statistically 
significant difference between non-detected GI-GVHD in biopsies collected from the 
rectosigmoid area versus detected elsewhere in the GI tract. Furthermore, biopsies from the 
rectosigmoid area were less reliable for detection of alternative diagnoses, such as CMV. Thus, 
full upper and lower endoscopy; combined upper endoscopy and sigmoidoscopy; or 
colonoscopy/ileocolonoscopy alone should be considered as procedures of choice in children 
with clinically suspected GI-GVHD.  
 
5.5 METHODOLOGICAL CONSIDERATIONS 
5.5.1 Strengths  
• In the context of HSCT, the most substantial difference between children and adult 
patients is related to differences in underlying diagnoses for the transplantation (10). 
Despite that, studies conducted specifically in pediatric HSCT patients are far less as 
common as corresponding studies including adult HSCT patients (183). All studies 
performed in this thesis included only children below 18 years of age.    
• In paper I, the influence on the result of chemotherapy given prior to HSCT was 
minimized since only children with JMML and MDS were included.   
• The study cohorts in paper II-IV only included children with endoscopy performed 
within one-year post-HSCT. That time limitation was used to avoid mixed indications 
for the endoscopic procedures (e.g. clinically suspected GI-aGVHD together with 
another indication). 
5.5.2 Weaknesses 
• The retrospective designs and limited sample sizes may have influenced the outcomes 
in all studies. 
• In paper I, the classification of the GI-aGVHD diagnosis was symptom-based and 
therefore less specific as compared to histopathology-based diagnosis (7). 
• In paper II, the vast majority had a note in the medical records indicating the motivation 
for the treatment change. However, potential misclassification may have occurred in 
those cases without this type of note.  
• The multicenter design of Study II may have influenced the results from CSHA due to 
interobserver and interinstitutional differences in the assessment of the GI-GVHD 
diagnosis (132, 134). 
• The RIHA in study III-IV was performed in a scientific setting, as a protocol-based 
procedure, by one pathologist. Thus, the setting differed from that of daily clinical 
practice. 
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6 CONCLUSIONS 
Paper I: The conditioning regimen of BuCyMel, compared with BuCy, resulted in an increased 
incidence of GI-aGVHD (stages 2-4) within 100 days post-HSCT in HSCT-treated children 
with JMML and MDS. However, the role of adding Mel to the BuCy conditioning regimen 
needs to be considered in a broader context, including the risk of relapse and probability of 
survival.  
Paper II: Endoscopy with histopathological assessment was found to influence the treatment 
decisions and should therefore be considered in children with suspected GI-aGVHD. 
Paper III: In children with symptom-based GI-aGVHD but without a CSHA-based 
confirmation of the diagnosis, a second histopathological assessment based on the NIH 2014 
criteria should be considered before performing a re-endoscopy.   
Paper IV: Sigmoidoscopy combined with upper endoscopy, colonoscopy/ileocolonoscopy, 
and full upper and lower endoscopy appear equally reliable for detecting GI-GVHD and should 
therefore be regarded as the preferred choices for an endoscopic procedure in children with 
clinically suspected GI-GVHD. However, in severely ill children with contraindications for 
general anesthesia or extensive endoscopy, sigmoidoscopy represents an acceptable option.  
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7 REFLECTIONS AND FUTURE PERSPECTIVES 
More than 50 years have passed since the first endoscopic procedure was performed in a child 
due to clinically suspected GI-GVHD. However, we are still dealing today with basic questions 
regarding the diagnosis of GI-GVHD in pediatric patients treated with HSCT.  
A striking finding in paper II-IV was that anti-GI-GVHD treatment was ongoing in the majority 
of the children at time point of the endoscopy. In fact, the anti-GI-GVHD treatments had been 
started approximately 13 days pre-endoscopically. One might argue that endoscopies 
performed under these circumstances are not true primary diagnostic procedures; rather, they 
are treatment controls or are performed to detect alternative diagnoses to GI-GVHD. Whether 
the lag time between the start of anti-GI-GVHD treatment and endoscopy was intentional is 
not known. However, causes and effects need to be clarified if the ambition is to switch to 
“true” diagnostic endoscopies in the future. A good start would be to initiate a survey 
highlighting the current clinical practice of diagnosis of GI-aGVHD in children in Sweden. 
Isolated upper GI tract aGVHD has been estimated to affect approximately 3 % of the adult 
patients undergoing HSCT (184). This manifestation of aGVHD, has been associated with a 
response rate to glucocorticoids of approximately 90 % (82, 83) and with an overall survival 
similar to that of patients without aGVHD (184). Based on these findings, a re-classification of 
isolated upper GI tract aGVHD from aGVHD grade 2 to aGVHD grade 0–1 has been proposed 
(184). Since this type of re-classification may have implications regarding the choice of anti-
GVHD treatment, isolated upper GI tract aGVHD represents an important topic of research 
also in pediatric HSCT patients.    
A growing number of publications are reporting that oral/enteral nutrition versus parenteral 
nutrition reduces the risk of development of GI-GVHD (110, 185). These results are in line 
with the concept that at least minimal enteral nutrition is beneficial for the GI tract (111). 
However, enteral nutrition as a treatment option has not been studied systematically in the 
context of pediatric GI-GVHD, even though one case report has been published (186). In 
pediatric Crohn disease (PCD), exclusively enteral nutrition is an established treatment 
modality with a clinical response rate equally as good as treatment with 1,6 mg 
methylprednisolone per kilogram bodyweight/day (187). Evaluation of the applicability of the 
knowledge derived from enteral nutrition treatment of PCD in pediatric GI-GVHD constitutes 
an important future research question.  
Dysbiosis has been associated with an increased risk for the development of GI-GVHD (69), 
and the lowest microbial diversity has been observed during the first month post-HSCT (69, 
188). Consequently, a potential strategy to prevent the development of GI-aGVHD might be 
prophylactic administration of probiotics or consideration of fecal microbiota transplantation 
(FMT) from healthy donors at the time of HSCT. Probiotics administered to children during 
the HSCT process have been considered safe (189). Furthermore, a placebo-controlled 
pediatric trial is currently ongoing to assess the efficacy of Lactobacillus plantarum in 
preventing the development of GI-aGVHD and CDI (ClinicalTrials.gov, NCT03057054).   
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Regarding FMT, different aspects of safety in the HSCT setting and the choice of method to 
perform the transplantation need clarification. At ClinicalTrials.gov, (August 18, 2020), using 
the search terms “gvhd and microbiota”, eleven out of thirty search results were registered trials 
with the objective of evaluating FMT as a treatment for severe aGVHD, most often GI-GVHD. 
However, no trials were found with the objective of evaluating the incidence of GI-aGVHD in 
prophylactic FMT administration.  
Probably the most important issue for the near future, from a clinical and a scientific viewpoint, 
is to continue to introduce a “common language” within the HSCT community. A “common 
language” with uniform definitions is a requirement for comparability of results from different 
studies. App-based diagnosis and grading of clinical GVHD, eGVHD, represents a strategy for 
establishing a “common language”. It was introduced approximately two years ago, with good 
preliminary results (190). Hopefully, a common histopathological language with uniform 
definition of the threshold of histopathology-based GI-GVHD is next in line, to create 
uniformity within the HSCT community.   
 

  47 
8 ACKNOWLEDGEMENTS 
To all the children that have participated in my studies, this thesis is as much yours as it is 
mine!!   
During my PhD process, five persons have been fundamentally important in getting the process 
rolling. Anna, my dear “almost wife,” you have contributed with outstanding support, positive 
input, and unconditional love all along the road. Kärlek! Britt and Thomas C, my dear friends 
and supervisors. You have opened the door to the world of science for me and carefully guided 
me on my way. My deepest respect and gratitude for all that you have done for me! Attila, the 
outstanding pathologist who has introduced me to the fascinating world of histopathology and 
who has performed the extensive work of re-assessment of all the biopsy slides included in this 
thesis. Attila, you are a Hero! Andreas, my dear brother and co-supervisor, the latter without 
knowing it! Andreas, many thanks for good advice, support, and for sharing your knowledge 
with me!      
Britt and Thomas (again), Moustapha and Jonas, my official supervisors, I owe you the greatest 
gratitude for all your support, help, and guidance during my PhD process! Many thanks! 
Moustapha, special thanks for being an unlimited source of inspiration and for many good 
advices, throughout my training! And Moustapha, thanks for countless laughs together!  
I have had the privilege of having the head of Division of Pediatrics, CLINTEC, as mentor. 
Björn, once upon a time, you employed me at the Department of Pediatric Gastroenterology, 
Hepatology and Nutrition at Karolinska University Hospital. I don’t think any of us, at that 
time, could have predicted that the most solid outcome of that employment would be this thesis! 
As my boss and mentor, I have never stopped being deeply impressed by the positive 
atmosphere that you create around you, your clear thinking, and your care for people in general 
and for me, in particular. Thanks, Björn! 
Many thanks to colleagues, friends, and co-writers at the non-Stockholm pediatric HSCT 
centers in Sweden who have participated and contributed to this thesis: Karin and Tom in 
Gothenburg, Jacek in Lund and Johan in Uppsala! Thanks for your co-operation and support!   
Thanks to Claude and Mats at CLINTEC for believing in me!  
Special thanks to my current and former boss at Sodertalje Hospital, Henrik and Sven, as well 
as to Mia. Henrik, Sven, and Mia, your flexibility, support, and overall consideration for me 
has been extremely important during this process! Many many thanks! 
Thilda, my angel and daughter, my deepest gratitude for your love and support! 
My gastro dream-team members at Sodertalje Hospital! First of all, Peter, my friend, soulmate, 
and (almost) roommate at Sodertalje Hospital. Thanks for always showing great interest in my 
work, for your support, and for all your help with the care of my patients when I have not been 
in charge! Also, many thanks to the other members of the dream team: Annika, Yvonne, and 
 48 
Jan! Bettan, you are not forgotten! Many thanks to Liz and to all other coworkers, at Sodertalje 
Hospital. 
The Britt team: Emma, Kristin, Lena, and Sara. Thanks to all of you for fruitful discussions 
and inspiration. Furthermore, to the oracle among PhD students at CLINTEC, Markus, thanks 
for your support and for sharing your knowledge with me! 
To my family and friends who never gave up on me! Thanks! 
Last but not least, many thanks to the staff at CLINTEC, to Stephan and all others at CAST, to 
colleagues and friends at the Division of Pediatric Gastroenterology and the Division of 
Pediatric Hematology, Immunology and HCT, Karolinska University Hospital, and finally to 
Claude, Anneli, Pär, and Peo, and all the other co-workers at Children’s Hospital Martina.     
 
8.1 FINANCIAL SUPPORT 
Studies included in this PhD project have received financial support from:  
o The Swedish Childhood Cancer Foundation  
o The Stockholm County Council Research Foundation (ALF)  
o Swedish Research Council (VR)  
o The Swedish Order of Freemasons  
o The Samariten Foundation for Paediatric Research  
o The Mary Béves Foundation 
 
 
 
 
 
 
 
 
 
 
 
 
  49 
9 SAMMANFATTNING PÅ SVENSKA  
 
9.1 BAKGRUND 
Cirka 40–50 barn (<18 år) i Sverige per år genomgår stamcellstransplantation. Blodcancer 
(leukemi) är den enskilt vanligaste orsaken till behandlingen. Vid en stamcellstransplantation 
förbehandlas, konditioneras, patienten med olika cellgifter, ibland även strålning, följt av att 
friska blod-stamceller från en annan person överförs. Hos mer än hälften av alla barn som 
genomgår stamcellstransplantation kommer givarens immunceller uppfatta den nya kroppen 
som “främmande”. Den sjukdom som då uppstår heter givare-mot-värd sjukdom (GVHD) och 
innebär att givarens immunceller angriper och skadar organ hos mottagaren. Vanligast är att 
GVHD drabbar huden, följt av magtarmkanalen och levern.  
Cirka vart fjärde barn (<18 år) som genomgår stamcellstransplantation drabbas av GVHD i 
magtarmkanalen (MT-GVHD).  Diagnostiken av MT-GVHD baseras i första hand på symptom 
såsom; diarré, viktnedgång, ont i magen, illamående och kräkningar. Emellertid, då dessa 
symptom är ospecifika och alltså förekommer vid en rad andra mag-tarmsjukdomar 
rekommenderas att slutgiltig MT-GVHD diagnos baseras på endoskopi (undersökning med 
kikarinstrument) av magtarmkanalen samtidigt som provbitar (biopsier) tas för en efterföljande 
mikroskopisk undersökning.  
Behandling av MT-GVHD, utgörs av kortison. Tyvärr är kortisonbehandling behäftad med 
risker, så som infektioner, högt blodsocker och högt blodtryck. Vid uteblivet behandlingssvar 
på kortison, halveras den förväntade två-årsöverlevnaden efter transplantationen.  
Denna avhandling syftar till: i) att jämföra två olika konditioneringar inför 
stamcellstransplantation avseende insjuknande in MT-GVHD, och ii) att utvärdera olika 
kliniska aspekter av mikroskopiskt baserad diagnostik av MT-GVHD hos barn. 
9.2 MATERIAL OCH METOD 
Samtliga studier som ingår i denna avhandlingen har haft en tillbakablickande - retrospektiv 
design. Studie 1 har inkluderat barn och ungdomar (<18 år) som transplanterats vid Karolinska 
Universitetssjukhuset Huddinge, mellan år 2000-2010, på grund av juvenil myelomonocyt 
leukemi (JMML) eller myelodysplastiskt syndrom (MDS) och som konditionerats med 
busulfan och cyklofosfamid, +/-  melfalan. Till studie 2-4 inkluderades barn och ungdomar 
(<18 år) som genomgått stamcellstransplantation vid något transplantationscenter i Sverige 
mellan år 2000-2012 och som dessutom, inom ett år efter transplantationen, genomgått 
endoskopi med biopsitagning på misstanke om MT-GVHD. Inkludering till studie 4 förutsatte 
dessutom att minst en biopsi tagits från ändtarm/nedre del av tjocktarm (sigmoideum), samt 
minst en från den uppåtstigande eller tvärgående delen av tjocktarmen. I studie 3-4 
genomfördes en förnyad, standardiserad mikroskopisk undersökning av samtliga biopsier. 
Denna undersökning utfördes av en patolog och var baserad på riktlinjer från amerikanska 
National Institutes of Health (NIH) 2014 avseende minimi-kriterier för mikroskopisk baserad 
 50 
MT-GVHD diagnos. I studie 3 jämfördes diagnoser fastställda vid den förnyade 
standardiserade mikroskopiska undersökningen med diagnoser som fastställdes vid den 
kliniska rutinmässiga mikroskopiska undersökningen.     
9.3 RESULTAT 
Studie 1: Tjugofem barn ingick i denna studie. Hos 44 % (8/17) som konditionerades med 
busulfan, cyklofosfamid och melfalan jämfört ingen (0/8) som konditionerades med busulfan 
och cyklofosfamid, utvecklades måttlig till svår MT-GVHD inom 100 dagar efter 
transplantationen (p<0.05). Studie 2: Sextioåtta barn med 91 endoskopitillfällen inkluderades. 
Hos 48 % (44/91), noterades förändringar i läkemedelsbehandlingen baserat på svar från 
klinisk rutinmässig mikroskopisk undersökning. Studie 3: Sjuttio barn med 92 
endoskopitillfällen inkluderades. MT-GVHD observerades efter 67 av 92 (73 %) 
endoskopitillfällen vid förnyad, standardiserad mikroskopisk undersökning och efter 50 av 92 
(54 %) endoskopitillfällen vid klinisk rutinmässig mikroskopisk undersökning (p = 0,014). 
Risken för en efterföljande ny endoskopi var högre om MT-GVHD enbart påvisades i den 
förnyade, standardiserade mikroskopiska undersökningen, jämfört med om vare sig klinisk 
rutinmässig eller standardiserad mikroskopisk undersökning påvisade MT-GVHD (p=0,005). 
Studie 4: Fyrtiofyra barn med 51 endoskopitillfällen deltog. MT-GVHD, baserad på förnyad, 
standardiserad mikroskopisk undersökning observerades vid 76 % (39/51) av endoskopiska 
tillfällena. I biopsier från ändtarm och nedre tjocktarm kunde förnyad, standardiserad 
mikroskopisk undersökning påvisa 85 % av alla mikroskopiskt fastställda fall av MT-GVHD. 
Motsvarande siffra för kombinerad biopsitagning från ändtarm och nedre tjocktarmen 
tillsammans med biopsier från övre magtarmkanalen var 97 %, vilket var samma resultat som 
om ändtarm, hela tjocktarmen och sista del av tunntarmen biopserades.   
9.4 SLUTSATSER 
• Tillägg av melfalan till busulfan och cyklofosfamid konditionering hos barn med 
JMML eller MDS ökar risken för utveckling av MT-GVHD  
• Endoskopi följt av mikroskopisk undersökning av insamlade magtarm-biopsier har en 
inverkan på valet av läkemedelsbehandling, och kan därför rekommenderas 
• Hos barn med symptom på MT-GVHD där klinisk rutinmässig mikroskopisk 
undersökning inte påvisat sjukdomen, bör en förnyad mikroskopisk undersökning, 
baserad på NIH 2014-kriterierna för MT-GVHD genomföras innan en ny endoskopi 
utförs 
• Endoskopi med biopsitagning vid misstänkt MT-GVHD hos barn bör omfatta antingen 
full övre och nedre endoskopi, endoskopi av ändtarm och nedre tjocktarm kombinerat 
med övre endoskopi eller full nedre endoskopi  
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